The US Food and Drug Administration has given its first approval to a treatment for Ebola virus, a potentially fatal disease affecting people in the Democratic Republic of the Congo (DRC) and several other African countries. The treatment, Inmazeb, is a mixture of three monoclonal antibodies which bind to the glycoprotein on the surface of the virus, blocking its attachment to cell receptors and preventing its entry into cells.
